PFE PF

PFE Pfizer, Inc.

Healthcare · Drug Manufacturers - General

5 · Fair Momentum 6.0 · Neutral At risk 16y streak

26.62

-1.59%

About the company

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

6.46%
226.32%
1.72
151.7B
35.03
0.76
25.89

52-week range

26.6
low 23.6 high 28.8
Yield Growth Momentum Safety Value Health

Dividend deep dive

Pfizer, Inc. (PFE), a healthcare company specializing in drug manufacturing, currently has a dividend yield of 6.87%. This yield is positioned near the high end of its 5-year range, which spans from 3.24% to 6.9%. The company's dividend safety is categorized as "at_risk," indicating potential challenges. However, based on Yield Theory, the stock's current price of $25.05 appears to be at a "fair" valuation, implying a price of $35.25.

Dividend history

Pfizer has a record of 16 consecutive years of dividend increases, granting it a "contender" status in the CCC list. Over the past three years, the dividend has grown at a compound annual growth rate (CAGR) of 2.44%, while the 5-year CAGR stands at 3.59%. The annual dividend has steadily risen from $0.9867 in 2014 to $1.68 in 2024, with a projected dividend of $1.72 for 2025. This history demonstrates consistent, albeit moderate, dividend growth.

Dividend safety

The company's dividend safety status is "at_risk," largely due to a high payout ratio of 131.3%. This figure is derived from the current annual dividend of $1.72 relative to earnings per share (EPS) of $1.31.

Quantic · Free

Read the rest of the safety verdict

Plus the key risks and what to watch next — free, no card.

AI-generated from Quantic's dividend data · Updated 17 Jul 2026 · Information, not financial advice.

Price history

59.0 41.2 23.3 2021 2022 2023 2024 2025 2026 2020-08 · 35.9 2020-09 · 34.8 2020-10 · 33.7 2020-11 · 38.3 2020-12 · 36.8 2021-01 · 35.9 2021-02 · 33.5 2021-03 · 36.2 2021-04 · 38.6 2021-05 · 38.7 2021-06 · 39.2 2021-07 · 42.8 2021-08 · 46.1 2021-09 · 43.0 2021-10 · 43.7 2021-11 · 53.7 2021-12 · 59.0 2022-01 · 52.7 2022-02 · 46.9 2022-03 · 51.8 2022-04 · 49.1 2022-05 · 53.0 2022-06 · 52.4 2022-07 · 50.5 2022-08 · 45.2 2022-09 · 43.8 2022-10 · 46.5 2022-11 · 50.1 2022-12 · 51.2 2023-01 · 44.2 2023-02 · 40.6 2023-03 · 40.8 2023-04 · 38.9 2023-05 · 38.0 2023-06 · 36.7 2023-07 · 36.1 2023-08 · 35.4 2023-09 · 33.2 2023-10 · 30.6 2023-11 · 30.5 2023-12 · 28.8 2024-01 · 27.1 2024-02 · 26.6 2024-03 · 27.8 2024-04 · 25.6 2024-05 · 28.7 2024-06 · 28.0 2024-07 · 30.5 2024-08 · 29.0 2024-09 · 28.9 2024-10 · 28.3 2024-11 · 26.2 2024-12 · 26.5 2025-01 · 26.5 2025-02 · 26.4 2025-03 · 25.3 2025-04 · 24.4 2025-05 · 23.5 2025-06 · 24.2 2025-07 · 23.3 2025-08 · 24.8 2025-09 · 25.5 2025-10 · 24.6 2025-11 · 25.7 2025-12 · 24.9 2026-01 · 26.4 2026-02 · 27.6 2026-03 · 28.1 2026-04 · 26.7 2026-05 · 26.2 2026-06 · 24.1 2026-07 · 25.1
Price

Dividend profile

Frequency
Quarterly
Growth (TTM)
+1.2%
CAGR 3y
+2.4%
+3.6%
16 years

(5-year)

Now 6.5%
3.2% avg 4.9% 6.9%

Payment calendar

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec

Dividend history

CAGR 3y +2.4% CAGR 5y +3.6% 16y streak
14 15 16 17 18 19 20 21 22 23 24 25

Per-share dividend by year

Quantic · Free

Unlock valuation & strategy

Two DDM fair values, margin of safety, sector value rank, Dividend Yield Theory, doubling time and max drawdown.

Debt & leverage

71.6%
1.25
0.85
Debt vs cash
Debt Cash
Total debt
64.7B USD
Total cash
13.1B USD
25.5B USD

Latest reported balance-sheet figures.

Held by 8 investors · watched by 3

Appears in these lists

PFE qualifies for these curated dividend rankings.

Appears in these comparisons

See how PFE stacks up against its dividend rivals.

Information, not financial advice.

Quantic · Free

Track PFE and your whole portfolio

Real yield, dividend safety, net-of-tax income and your path to freedom — free, no broker connection.

€0

Need more? Pro adds portfolios, options income tracking & more AI. See Pro →